The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
999
April 25, 1997
View Complete Issue         Table of Contents 2019 
Valsartan for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Valsartan for Hypertension
April 25, 1997 (Issue: 999)
Valsartan (Diovan - Novartis), a non-peptide tetrazole, is the second angiotensin II receptor antagonist approved for oral treatment of hypertension by the US Food and Drug Administration. The first was losartan (Cozaar - Medical Letter, 37:57,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Valsartan for Hypertension
Article code: 999b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.